IPUBLIC RECORDSEXCHANGERECEIPTSloadinglive·IMONEY TRAILEXCHANGESOURCESverifyinglive·IDATA SOURCESEXCHANGEFILINGSpublic recordslive·IPUBLIC RECORDSEXCHANGERECEIPTSloadinglive·IMONEY TRAILEXCHANGESOURCESverifyinglive·IDATA SOURCESEXCHANGEFILINGSpublic recordslive·
FEDERAL LOBBYING RECORDS

LOBBYING FILINGS AND MARKET CONTEXT

Indexed federal lobbying filings mapped to clients, registrants, and public-company tickers. Transaction dates are compared with filing periods to identify date-proximity review flags. Proximity does not establish coordination, influence, or wrongdoing.

Filings tracked
20,641
thru 2026-07-15
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,260
paying companies
Tickers targeted
1,219
public companies

Clients by reported amount

#ClientFilingsTotal $
1PFIZER INC.PFE48$46.9M
2GENERAL MOTORS COMPANYGM61$46.8M
3META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA13$45.0M
4VISA INC.V46$37.7M
5AMAZON.COM SERVICES LLCAMZN37$32.8M
6LOCKHEED MARTIN CORPORATIONLMT76$29.1M
7FEDEX CORPORATIONFDXW71$27.9M
8ELI LILLY AND COMPANYLLY60$27.4M
9ALTRIA CLIENT SERVICES LLCMO147$25.3M
10COMCAST CORPORATIONCMCSV183$24.9M
11AMGEN INCAMGN19$24.9M
12MERCK & CO INCMRK14$24.0M
13SOUTHERN COMPANYSO54$23.9M
14GOOGLE CLIENT SERVICES LLCGOOGL83$22.8M
15APPLE INCAAPL9$22.1M
16T-MOBILE USA INC.TMUS131$21.3M
17UNITEDHEALTH GROUP INCUNH19$20.4M
18VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ41$20.1M
19OCCIDENTAL PETROLEUM CORPORATIONOXY32$19.8M
20MICROSOFT CORPORATIONMSFT107$18.9M
21QUALCOMM INCORPORATEDQCOM40$17.2M
22BOEING COMPANYBA24$17.0M
23GENERAL DYNAMICS CORPGD11$17.0M
24THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI13$16.9M
25ORACLE CORPORATIONORCL60$16.8M

Mapped tickers by reported amount

#TickerFilingsTotal $
1META
Meta Platforms Inc.
134$50.3M
2PFE
Pfizer Inc.
89$48.7M
3GM
General Motors Company
103$48.4M
4V
Visa Inc.
47$37.7M
5AMZN
Amazon.com Inc.
82$35.4M
6LMT
Lockheed Martin Corporation
92$29.5M
7FDX
FedEx Corporation
83$28.4M
8LLY
Eli Lilly and Company
88$28.4M
9AMGN
Amgen Inc.
100$28.0M
10MRK
Merck & Co. Inc.
92$27.5M
11AAPL
Apple Inc.
66$27.0M
12GOOGL
Alphabet Inc. Class A
128$26.8M
13MO172$26.4M
14SO
Southern Company
110$26.2M
15UNH
UnitedHealth Group Inc.
68$24.0M
16VZ
Verizon Communications Inc.
119$23.8M
17TMUS170$22.9M
18CHTR142$22.8M
19GD
General Dynamics Corporation
131$22.6M
20T
AT&T Inc.
137$21.7M
21ORCL
Oracle Corporation
135$20.8M
22CMCSA
Comcast Corporation
142$20.5M
23OXY
Occidental Petroleum Corporation
38$20.1M
24CI
The Cigna Group
64$19.9M
25MSFT
Microsoft Corporation
126$19.3M

🆕 Filtered Filings · OMEROS CORPORATION

clear filters
DateTickerClientRegistrantAmountIssue
2026-07-15OMEROMEROS CORPORATIONTHE NICKLES GROUP, LLC$0Monitored separate payment policy for nonopioid alternatives. Monitored issues involving rare disease therapies. Monitored issues related to rare pediatric disease and Priority Review Vouchers (PRVs).
2026-04-19OMEROMEROS CORPORATIONAQUIA GROUP, LLC$0
2026-04-08OMEROMEROS CORPORATIONTHE NICKLES GROUP, LLC$0Monitored separate payment policy for nonopioid alternatives. Monitored issues involving rare disease therapies. Monitored issues related to rare pediatric disease and Priority Review Vouchers (PRVs).
2026-01-20OMEROMEROS CORPORATIONAQUIA GROUP, LLC$90KIssues related to rare pediatric disease
2026-01-15OMEROMEROS CORPORATIONTHE NICKLES GROUP, LLC$0Monitored separate payment policy for nonopioid alternatives. Monitored issues involving rare disease therapies. Monitored issues related to rare pediatric disease and Priority Review Vouchers (PRVs).
2025-10-20OMEROMEROS CORPORATIONAQUIA GROUP, LLC$90KIssues related to rare pediatric disease
2025-10-09OMEROMEROS CORPORATIONTHE NICKLES GROUP, LLC$30KMonitored separate payment policy for nonopioid alternatives. Issues involving rare disease therapies. Issues related to rare pediatric disease and Priority Review Vouchers (PRVs).
2025-07-21OMEROMEROS CORPORATIONAVENUE SOLUTIONS$80KIssues related to the FDA and treatment for rare disease Issues related to the expiration/extension of Priority Review Vouchers (PRVs) for rare disease; S. 891, Bipartisan Health Care Act; H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (PL 119-4)
2025-07-21OMEROMEROS CORPORATIONAQUIA GROUP, LLC$50KIssues related to rare pediatric disease
2025-07-18OMEROMEROS CORPORATIONGRAYROBINSON PA$0
2025-07-16OMEROMEROS CORPORATIONAQUIA GROUP, LLC$0Issues related to the FDA.
2025-07-14OMEROMEROS CORPORATIONTHE NICKLES GROUP, LLC$40KMonitored separate payment policy for nonopioid alternatives. Issues involving rare disease therapies. Monitored issues related to rare pediatric disease and Priority Review Vouchers (PRVs).
2025-07-11OMEROMEROS CORPORATIONTHE PETRIZZO GROUP, INC.$0
2025-06-11OMEROMEROS CORPORATIONAVOQ, LLC$20KGeneral monitoring of health care issues
2025-05-06OMEROMEROS CORPORATIONLESTER HEALTH LAW PLLC$45KHospital Outpatient and ASC PPS proposed rule
2025-04-21OMEROMEROS CORPORATIONAVENUE SOLUTIONS$80KIssues related to the expiration/extension of Priority Review Vouchers (PRVs) for rare disease; S. 891, Bipartisan Health Care Act; H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (PL 119-4) Issues related to the FDA and treatment for rare disease
2025-04-21OMEROMEROS CORPORATIONAVOQ, LLC$60KGeneral monitoring of health care issues
2025-04-20OMEROMEROS CORPORATIONGRAYROBINSON PA$45KSeparate payment policies for non-opioid alternatives.
2025-04-18OMEROMEROS CORPORATIONTHE NICKLES GROUP, LLC$40KMonitored separate payment policy for nonopioid alternatives. Issues involving rare disease therapies. Issues related to rare pediatric disease and Priority Review Vouchers (PRVs).
2025-04-15OMEROMEROS CORPORATIONTHE PETRIZZO GROUP, INC.$50KDevelopment and execution of initiatives involving multiple Omeros pipeline targets before the U.S. Government, including funding collaborations associated with COVID, Cancer, and addition within the Department of HHS, NIH, BARDA, and the White House. FDA Rare Disease Center of Excellence Development and execution of initiatives involving multiple Omeros pipeline targets before the U.S. Government, including funding collaborations associated with COVID, Cancer, and addition within the Department of HHS, NIH, BARDA, and the White House. FDA Rare Disease Center of Excellence
2025-02-04OMEROMEROS CORPORATIONLESTER HEALTH LAW PLLC$45Kimplementation of the "No Pain" Act; Hospital Outpatient Prospective Payment System;
2025-01-21OMEROMEROS CORPORATIONAVENUE SOLUTIONS$80KMonitor implementation of separate payment policies for non-opioid alternatives Issues related to the FDA and treatment for rare disease
2025-01-21OMEROMEROS CORPORATIONAVOQ, LLC$60KGeneral monitoring of health care issues
2025-01-21OMEROMEROS CORPORATIONGRAYROBINSON PA$45KSeparate payment policies for nonopioid alternatives.